Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study

Background: COVID-19 continues to pose a threat to immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 with the benefit of a prolonged half-life. Although approved for COVID-19 prevent...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dimitrios Basoulis, Elpida Mastrogianni, Georgios Karamanakos, Aikaterini Gkoufa, Vasiliki E. Georgakopoulou, Sotiria Makrodimitri, Maria N. Gamaletsou, Antonios Markogiannakis, Nikolaos V. Sipsas
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-08-01
Edice:	Viruses
Témata:	COVID-19 monoclonal antibodies tixagevimab/cilgavimab immunocompromised patients
On-line přístup:	https://www.mdpi.com/1999-4915/16/8/1345
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!